{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:19:34Z","timestamp":1772165974645,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:00Z","timestamp":1694822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:00Z","timestamp":1694822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Science, Technology & Innovation Funding Authority"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Genitourinary syndrome of menopause (GSM) is a common and disturbing issue in the postmenopausal period. Unlike vasomotor symptoms, it has a progressive trend. Our study aims to evaluate the efficacy and safety of oxytocin gel versus placebo gel in postmenopausal women with GSM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic review and meta-analysis synthesizing randomized controlled trials (RCTs) from Web of Science, SCOPUS, PubMed, and Cochrane Central Register of Controlled Trials databases on January 18, 2023. Keywords such as \u201coxytocin,\u201c \u201cintravaginal,\u201c \u201cvaginal,\u201c \u201catrophic,\u201c and \u201catrophy\u201d were used. We used Review Manager (RevMan) version 5.4 in our analysis. We used the risk ratio (RR) for dichotomous outcomes and the mean difference (MD) for continuous outcomes; both were presented with the corresponding 95% confidence interval (CI) and were calculated with the Mantel-Haenszel or inverse variance statistical method. Cochrane\u2019s Q test and the I\n                      <jats:sup>2<\/jats:sup>\n                      statistic were used as measures of statistical inconsistency and heterogeneity. The Cochrane Risk of Bias Tool for RCTs was used for the quality assessment of the included studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven studies with 631 patients were included. Regarding the maturation index, there was a statistically insignificant increase in the oxytocin arm (MD\u2009=\u200912.34, 95% CI (-12.52-37.19),\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.33). Clinically assessed vaginal atrophy showed a statistically significant reduction in the oxytocin group (RR\u2009=\u20090.32, 95% CI (0.23\u2009\u2212\u20090.10),\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.00001). For dyspareunia, vaginal pH, and histological evaluation of vaginal atrophy, there was a statistically insignificant difference between the two groups (RR\u2009=\u20091.02, 95% CI (0.82\u20131.27),\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.84), (MD = -0.74, 95% CI (-1.58-0.10),\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.08), and (MD = -0.38, 95% CI (-0.82-0.06),\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.09), respectively. There was no significant difference in the safety profile between the two groups as measured by endometrial thickness (MD\u2009=\u20090.00, 95% CI (-0.23-0.23),\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.99).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although oxytocin has been proposed as a viable alternative to estrogen in the treatment of GSM, our findings show the opposite. Larger, high-quality RCTs are needed to confirm or refute our results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>PROSPERO registration\u00a0number CRD42022334357.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-023-02645-0","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T08:01:25Z","timestamp":1694851285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The efficacy of oxytocin gel in postmenopausal women with vaginal atrophy: an updated systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Ramadan Abdelmoez","family":"Farahat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazem Mohamed","family":"Salamah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelrahman","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esraa","family":"Hamouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Hashemy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heba","family":"Hamouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Samir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imane","family":"Chenfouh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Marey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina M.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsayed","family":"Farag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Abd-Elgawad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsayed","family":"Eldesouky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,16]]},"reference":[{"key":"2645_CR1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/oxfordjournals.aje.a009609","volume":"148","author":"A Morabia","year":"1998","unstructured":"Morabia A, Costanza MC. International Variability in Ages at Menarche, First Livebirth, and Menopause. Am J Epidemiol. 1998;148:1195\u2013205.","journal-title":"Am J Epidemiol"},{"key":"2645_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgaa764","volume":"106","author":"N Santoro","year":"2021","unstructured":"Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs, symptoms, and Management Options. J Clin Endocrinol Metab. 2021;106:1\u201315.","journal-title":"J Clin Endocrinol Metab"},{"key":"2645_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.mcna.2015.01.006","volume":"99","author":"TA Takahashi","year":"2015","unstructured":"Takahashi TA, Johnson KM, Menopause. Med Clin North Am. 2015;99:521\u201334.","journal-title":"Med Clin North Am"},{"key":"2645_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","volume":"21","author":"DJ Portman","year":"2014","unstructured":"Portman DJ, Gass MLS. Genitourinary syndrome of menopause. Menopause. 2014;21:1063\u20138.","journal-title":"Menopause"},{"key":"2645_CR5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7586","author":"K Angelou","year":"2020","unstructured":"Angelou K, Grigoriadis T, Diakosavvas M, Zacharakis D, Athanasiou S. The Genitourinary Syndrome of Menopause: an overview of the recent data. Cureus. 2020. https:\/\/doi.org\/10.7759\/cureus.7586.","journal-title":"Cureus"},{"key":"2645_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/13697137.2017.1421921","volume":"21","author":"E Moral","year":"2018","unstructured":"Moral E, Delgado JL, Carmona F, Caballero B, Guill\u00e1n C, Gonz\u00e1lez PM, et al. Genitourinary syndrome of menopause. Prevalence and quality of life in spanish postmenopausal women. The GENISSE study. Climacteric. 2018;21:167\u201373.","journal-title":"Climacteric"},{"key":"2645_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.maturitas.2015.09.001","volume":"83","author":"F Palma","year":"2016","unstructured":"Palma F, Volpe A, Villa P, Cagnacci A. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas. 2016;83:40\u20134.","journal-title":"Maturitas"},{"key":"2645_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3109\/13697137.2011.647840","volume":"15","author":"RE Nappi","year":"2012","unstructured":"Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) \u2013 results from an international survey. Climacteric. 2012;15:36\u201344.","journal-title":"Climacteric."},{"key":"2645_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/GME.0000000000001260","volume":"26","author":"RE Nappi","year":"2019","unstructured":"Nappi RE, Palacios S, Bruyniks N, Particco M, Panay N. The burden of vulvovaginal atrophy on women\u2019s daily living: implications on quality of life from a face-to-face real-life survey. Menopause. 2019;26:485\u201391.","journal-title":"Menopause"},{"key":"2645_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.5114\/pm.2018.81741","volume":"17","author":"J Szyma\u0144ski","year":"2018","unstructured":"Szyma\u0144ski J, Zar\u0119ba K, Jakiel G, S\u0142abuszewska-J\u00f3\u017awiak A. Genitourinary syndrome of menopause \u2013 is the problem solved? State of the art 2018. Menopausal Rev. 2018;17:173\u20139.","journal-title":"Menopausal Rev"},{"key":"2645_CR11","doi-asserted-by":"crossref","unstructured":"Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016:CD001500.","DOI":"10.1002\/14651858.CD001500.pub3"},{"key":"2645_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/2053369117693148","volume":"23","author":"TK Kallak","year":"2017","unstructured":"Kallak TK, Uvn\u00e4s-Moberg K. Oxytocin stimulates cell proliferation in vaginal cell line Vk2E6E7. Post Reprod Heal. 2017;23:6\u201312.","journal-title":"Post Reprod Heal"},{"key":"2645_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/2053369120946645","volume":"27","author":"Z Ghorbani","year":"2021","unstructured":"Ghorbani Z, Mirghafourvand M. The efficacy and safety of intravaginal oxytocin on vaginal atrophy: a systematic review. Post Reprod Heal. 2021;27:30\u201341.","journal-title":"Post Reprod Heal"},{"key":"2645_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1258\/mi.2011.011030","volume":"17","author":"AF Jonasson","year":"2011","unstructured":"Jonasson AF, Edwall L, Uvn\u00e4s-Moberg K. Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study. Menopause Int. 2011;17:120\u20135.","journal-title":"Menopause Int"},{"key":"2645_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/13697137.2017.1421924","volume":"21","author":"HA Torky","year":"2018","unstructured":"Torky HA, Taha A, Marie H, El-Desouky E, Raslan O, Moussa AA, et al. Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. Climacteric. 2018;21:174\u20138.","journal-title":"Climacteric"},{"key":"2645_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/MDER.S265824","volume":"13","author":"A Fianu Jonasson","year":"2020","unstructured":"Fianu Jonasson A, Bixo M, Sundstr\u00f6m Poromaa I, \u00c5strom M. Safety and Efficacy of an Oxytocin Gel and an equivalent gel but without hormonal ingredients (Vagivital\u00ae Gel) in Postmenopausal women with symptoms of Vulvovaginal Atrophy: a Randomized, double-blind controlled study. Med Devices Evid Res. 2020;13:339\u201347.","journal-title":"Med Devices Evid Res"},{"key":"2645_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/0092623X.2020.1738606","volume":"46","author":"P Abedi","year":"2020","unstructured":"Abedi P, Zohrabi I, Ansari S, Maraghi E, Maram NS, Houshmand G. The impact of oxytocin vaginal gel on sexual function in Postmenopausal Women: a Randomized Controlled Trial. J Sex Marital Ther. 2020;46:377\u201384.","journal-title":"J Sex Marital Ther"},{"key":"2645_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/2053369115577328","volume":"21","author":"SH Al-Saqi","year":"2015","unstructured":"Al-Saqi SH, Uvn\u00e4s-Moberg K, Jonasson AF. Intravaginally applied oxytocin improves post-menopausal vaginal atrophy. Post Reprod Heal. 2015;21:88\u201397.","journal-title":"Post Reprod Heal"},{"key":"2645_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2053369116629042","volume":"22","author":"SH Al-Saqi","year":"2016","unstructured":"Al-Saqi SH, Jonasson AF, Naess\u00e9n T, Uvn\u00e4s-Moberg K. Oxytocin improves cytological and histological profiles of vaginal atrophy in postmenopausal women. Post Reprod Heal. 2016;22:25\u201333.","journal-title":"Post Reprod Heal"},{"key":"2645_CR20","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1111\/j.1755-5949.2010.00185.x","volume":"16","author":"C Viero","year":"2010","unstructured":"Viero C, Shibuya I, Kitamura N, Verkhratsky A, Fujihara H, Katoh A, et al. REVIEW: Oxytocin: crossing the bridge between Basic Science and Pharmacotherapy. CNS Neurosci Ther. 2010;16:e138\u201356.","journal-title":"CNS Neurosci Ther"},{"key":"2645_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.31887\/DCNS.2015.17.4\/pkirsch","volume":"17","author":"P Kirsch","year":"2015","unstructured":"Kirsch P. Oxytocin in the socioemotional brain: implications for psychiatric disorders. Dialogues Clin Neurosci. 2015;17:463\u201376.","journal-title":"Dialogues Clin Neurosci"},{"key":"2645_CR22","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1002\/jcph.961","volume":"57","author":"EI Nielsen","year":"2017","unstructured":"Nielsen EI, Al-Saqi SH, Jonasson AF, Uvn\u00e4s-Moberg K. Population Pharmacokinetic Analysis of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women. J Clin Pharmacol. 2017;57:1573\u201381.","journal-title":"J Clin Pharmacol"},{"key":"2645_CR23","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLOS Med. 2021;18:e1003583.","journal-title":"PLOS Med"},{"key":"2645_CR24","volume-title":"Cochrane Handbook for systematic reviews of interventions","author":"JPT Higgins","year":"5391","unstructured":"Higgins JPT. In: Thomas J, Chandler J, Cumpston M, Li T, Page MJWV, editors. Cochrane Handbook for systematic reviews of interventions. 2nd Editio ed. Chichester (UK): John Wiley & Sons, Ltd; 5391.","edition":"2"},{"key":"2645_CR25","unstructured":"Green S, Higgins P, Alderson P, Clarke M, Mulrow DC, Oxman DA. Cochrane Handbook: Cochrane Reviews: ch 8. Assessing risk of bias in included studies. Cochrane Handb Syst Rev Interv. 2011;1:3\u201311."},{"key":"2645_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"2645_CR27","unstructured":"Review Manager (RevMan). [Computer program]. Version 5.4. The Cochrane Collaboration; 2020."},{"key":"2645_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12905-020-00935-5","volume":"20","author":"I Zohrabi","year":"2020","unstructured":"Zohrabi I, Abedi P, Ansari S, Maraghi E, Shakiba Maram N, Houshmand G. The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial. BMC Womens Health. 2020;20:108.","journal-title":"BMC Womens Health"},{"key":"2645_CR29","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.ajog.2016.07.045","volume":"215","author":"J Gandhi","year":"2016","unstructured":"Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215:704\u201311.","journal-title":"Am J Obstet Gynecol"},{"key":"2645_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0378-5122(94)00863-3","volume":"21","author":"K Nilsson","year":"1995","unstructured":"Nilsson K, Risberg B, Heimer G. The vaginal epithelium in the postmenopause \u2014 cytology, histology and pH as methods of assessment. Maturitas. 1995;21:51\u20136.","journal-title":"Maturitas"},{"key":"2645_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(03)14065-2","volume":"362","author":"E Banks","year":"2003","unstructured":"Banks E, Beral V, Bull D, Reeves G, Austoker J, English R, et al. Breast cancer and hormone-replacement therapy in the million women study. Lancet. 2003;362:419\u201327.","journal-title":"Lancet"},{"key":"2645_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1152\/physrev.2001.81.2.629","volume":"81","author":"G Gimpl","year":"2001","unstructured":"Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and Regulation. Physiol Rev. 2001;81:629\u201383.","journal-title":"Physiol Rev"},{"key":"2645_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1365-2826.1990.tb00458.x","volume":"2","author":"J Peter","year":"1990","unstructured":"Peter J, Burbach H, Adan RAH, Tol HHM, Verbeeck MAE, Axelson JF, et al. Regulation of the Rat Oxytocin Gene by Estradiol. J Neuroendocrinol. 1990;2:633\u20139.","journal-title":"J Neuroendocrinol"},{"key":"2645_CR34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/j.0953-8194.2004.01165.x","volume":"16","author":"P Cassoni","year":"2004","unstructured":"Cassoni P, Sapino A, Marrocco T, Chini B, Bussolati G. Oxytocin and Oxytocin Receptors in Cancer cells and proliferation. J Neuroendocrinol. 2004;16:362\u20134.","journal-title":"J Neuroendocrinol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02645-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-023-02645-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02645-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T19:04:00Z","timestamp":1700593440000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-023-02645-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,16]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2645"],"URL":"https:\/\/doi.org\/10.1186\/s12905-023-02645-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2578969\/v1","asserted-by":"object"}]},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,16]]},"assertion":[{"value":"12 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"494"}}